CC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chemours Co does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While there are some positive catalysts, the financial performance and mixed analyst ratings suggest a cautious approach.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 79.695, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key pivot levels, with resistance at 21.056 and 22.153.
The company also recorded a significant options volume of 43,836 contracts, reflecting market interest.
The company's Q4 financials show a revenue decline of -2.13% YoY and a drop in gross margin by -39.19%. Insider and hedge fund trading trends are neutral, and there is no recent congress trading data. Analyst ratings are mixed, with some firms maintaining neutral or equal weight ratings.
In Q4 2025, revenue dropped to $1.33 billion (-2.13% YoY). Net income improved to -$61 million (+408.33% YoY), and EPS increased to -0.41 (+412.50% YoY). However, gross margin declined significantly to 11.95% (-39.19% YoY).
Recent analyst ratings are mixed. Mizuho raised the price target to $21 with an Outperform rating, while UBS set a high target of $23 with a Buy rating. However, firms like Goldman Sachs and JPMorgan maintain neutral ratings, and BMO Capital lowered its price target to $19.
